The use of carer assisted adherence therapy for people with Parkinson's disease and their carers (CAAT-PARK): Study protocol for a randomised controlled trial

Trials

Volumn 12, Issue , 2011, Pages

  Daley, David J ^a,b   Deane, Katherine H O ^a   Gray, Richard J ^a   Worth, Paul F ^b   Clark, Allan B ^a   Sabanathan, Kanagasabesan ^b   Pfeil, Michael ^a   Myint, Phyo K ^a,b  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Adherence; Adherence therapy; Medication; Parkinson's disease

Indexed keywords

ARTICLE; CAREGIVER; CARER ASSISTED ADHERENCE THERAPY; DECISION MAKING; HUMAN; PARKINSON DISEASE; PATIENT COMPLIANCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); THERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; RANDOMIZED CONTROLLED TRIAL;

ANTIPARKINSON AGENT;

ANTIPARKINSON AGENTS; CAREGIVERS; CLINICAL PROTOCOLS; HUMANS; MEDICATION ADHERENCE; PARKINSON DISEASE;

EID: 83255164239     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-12-251     Document Type: Article

References (59)

1. NICE The National Collaborating Centre for Chronic Conditions. Parkinson's Disease: National clinical guideline for diagnosis and management in primary and secondary care. 2006, London: Royal College of Physicians, NICE.
2. Schapira AHV, Obeso J. Timing of treatment initiation in Parkinson's disease: A need for reappraisal?. Ann Neurol 2006, 59(3):559-562. 10.1002/ana.20789, 16489611.
3. Albanese A. Diagnostic criteria for Parkinson's disease. Neurological Sciences 2003, 24(0):s23-s26. 10.1007/s100720300032, 12774207.
4. Chaudhuri KR, Healy DG, Schapira AHV. Non-motor symptoms of Parkinson's disease: diagnosis and management. The Lancet Neurology 2006, 5(3):235-245.
5. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Movement Disorders 2005, 20(10):1255-1263. 10.1002/mds.20527, 16041803.
6. Aarsland D, Kurz MW. The Epidemiology of Dementia Associated with Parkinson's Disease. Brain Pathology 2010, 20(3):633-639. 10.1111/j.1750-3639.2009.00369.x, 20522088.
7. Schapira AHV, Emre M, Jenner P, Poewe W. Levodopa in the treatment of Parkinson's disease. European Journal of Neurology 2009, 16(9):982-989. 10.1111/j.1468-1331.2009.02697.x, 19538218.
8. Schapira AHV. Treatment Options in the Modern Management of Parkinson Disease. Arch Neurol 2007, 64(8):1083-1088. 10.1001/archneur.64.8.1083, 17698697.
9. Leoni O, Martignoni E, Cosentino M, Michielotto D, Calandrella D, Zangaglia R, Riboldazzi G, Oria C, Lecchini S, Nappi G, et al. Drug prescribing patterns in Parkinson's disease: a pharmacoepidemiological survey in a cohort of ambulatory patients. Pharmacoepidemiology and Drug Safety 2002, 11(2):149-157. 10.1002/pds.682, 11998540.
10. Tan EK, Yeo AP, Tan V, Pavanni R, Wong MC. Prescribing pattern in Parkinson's disease: are cost and efficacy overriding factors?. Int J Clin Pract 2005, 59(5):511-514. 10.1111/j.1368-5031.2005.00426.x, 15857344.
11. Schapira A, Agid Y, Barone P, Jenner P, Lemke M, Poewe W, Rascol O, Reichmann H, Tolosa E. Perspectives on recent advances in the understanding and treatment of Parkinson's disease. European Journal of Neurology 2009, 16(10):1090-1099. 10.1111/j.1468-1331.2009.02793.x, 19723294.
12. Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004, 61(7):1044-1053.
13. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson's Disease Who Were Treated with Ropinirole or Levodopa. New England Journal of Medicine 2000, 342(20):1484-1491. 10.1056/NEJM200005183422004, 10816186.
14. Bainbridge JL, Ruscin J. Challenges of Treatment Adherence in Older Patients with Parkinson's Disease. Drugs Aging 2009, 26(2):145-155. 10.2165/0002512-200926020-00006, 19220071.
15. Grosset KA, Reid JL, Grosset DG. Medicine-taking behavior: Implications of suboptimal compliance in Parkinson's disease. Movement Disorders 2005, 20(11):1397-1404. 10.1002/mds.20525, 16092116.
16. Valldeoriola F, Coronell C, Pont C, Buongiorno MT, Cámara A, Gaig C, Compta Y, . the members of the ASG Socio-demographic and clinical factors influencing the adherence to treatment in Parkinson's disease: the ADHESON study. European Journal of Neurology 2010, no-no, the members of the ASG.
17. Rigby D. Adherence assessment tools: Drugs dont work when they're not taken. The Australian Journal of Pharmacy 2007, 88:32-33.
18. Haynes RB, McDonald HP, Garg AX. Helping Patients Follow Prescribed Treatment. JAMA: The Journal of the American Medical Association 2002, 288(22):2880-2883.
19. NICE Medicines Adherence: Involving patients in decisions about prescribed medications and supporting adherence. NICE Clinical Guidelines 76. Developed by the National Collaborative Centre for Primary Care 2009, NICE.
20. Osterberg L, Blaschke T. Adherence to Medication. New England Journal of Medicine 2005, 353(5):487-497. 10.1056/NEJMra050100, 16079372.
21. Grosset D, . European PDTCSG Therapy adherence issues in Parkinson's disease. Journal of the Neurological Sciences 2010, 289(1-2):115-118. 10.1016/j.jns.2009.08.053, 19793590, European PDTCSG.
22. Leopold NA, Polansky M, Hurka MR. Drug adherence in Parkinson's disease. Movement Disorders 2004, 19(5):513-517. 10.1002/mds.20041, 15133814.
23. Grosset KA, Bone I, Grosset DG. Suboptimal medication adherence in Parkinson's disease. Movement Disorders 2005, 20(11):1502-1507. 10.1002/mds.20602, 16037924.
24. Chaudhuri K, Taurah L, MacMahon D. PD LIFE: a prospective multi-centre longitudinal audit of quality of life in Parkinson's disease across the UK. J Neurol Neurosurg Psychiatry 2004, 75:516.
25. O'Sullivan SS, Evans AH, Lees AJ. Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management. CNS Drugs 2009, 23(2):157-170. 10.2165/00023210-200923020-00005, 19173374.
26. Péchevis M, Clarke CE, Vieregge P, Khoshnood B, Deschaseaux-Voinet C, Berdeaux G, Ziegler M, . the Trial Study G Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. European Journal of Neurology 2005, 12(12):956-963. 10.1111/j.1468-1331.2005.01096.x, 16324089, the Trial Study G.
27. A'Campo L, Spliethoff-Kamminga N, Macht M, Roos R. Caregiver education in Parkinson's disease: Formative evaluation of a standardized program in seven European countries. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care & Rehabilitation 2010, 19(1):55-64. 10.1007/s11136-009-9559-y, 20549177.
28. Cifu D, Carne W, Brown R, Pegg P, Ong J, Qutubuddin A, Baron M. Caregiver distress in parkinsonism. Journal of Rehabilitation Research and Development 2006, 43(4):499-508. 10.1682/JRRD.2005.08.1365, 17123189.
29. Kemp R, Kirov G, Everitt B, Haywood P, David A. Ramdomised Controlled Trial of Compliance Therapy: 18-month follow-up. British Journal of Psychiatry 1998, 172:413. 10.1192/bjp.172.5.413, 9747403.
30. Gray R, White J, Schulz M, Abderhalden C. Enhancing medication adherence in people with schizophrenia: An international programme of research. International Journal of Mental Health Nursing 2010, 19(1):36-44. 10.1111/j.1447-0349.2009.00649.x, 20074202.
31. Alhalaiqa F, Deane K, Nawafleh A, Clark A, Gray R. Adherence therapy for medication non-compliant patients with hypertension: a randomised controlled trial. Journal of Human Hypertension 2011,
32. Staring ABP, Van der Gaag M, Koopmans GT, Selten JP, Van Beveren JM, Hengevald MW, Loonen AJM, Mulder CL. Treatment adherence therapy in people with psychotic disorders: randomised controlled trial. The British Journal of Psychiatry 2010, 197:448-455. 10.1192/bjp.bp.110.077289, 21119150.
33. Grosset D, Antonini A, Canesi M, Pezzoli G, Lee A, Shaw K, Cubo E, Martinez-Martin P, Rascol O, Negre-Pages L, et al. Adherence to Antiparkinson Medication in a Multicenter European Study. Movement Disorders 2009, 24(6):826-832. 10.1002/mds.22112, 19191340.
34. Evans AH, Lawrence AD, Potts J, Appel S, Lees AJ. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology 2005, 65(10):1570-1574. 10.1212/01.wnl.0000184487.72289.f0, 16301483.
35. Morisky D, Green LW, Levin DM. Concurrent and Predictive Validity of a Self-reported Measure of Medication Adherence. MEDICAL CARE 1986, 24(1):67-74. 10.1097/00005650-198601000-00007, 3945130.
36. Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Quality of Life Research 1995, 4(3):241-248. 10.1007/BF02260863, 7613534.
37. Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, Stern MB, Tilley BC, Dodel R, Dubois B, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Movement Disorders 2007, 22(1):41-47. 10.1002/mds.21198, 17115387.
38. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: The development and evaluation of a new method for assessing the cognitive representation of medication. Psychology & Health 1999, 14(1):1-24. 3220697, 22125612.
39. Brooks R. EuroQol: the current state of play. Health policy 1996, 37(1):53-72. 10.1016/0168-8510(96)00822-6, 10158943.
40. Cousins R, Davies AD, Turnbull CJ, Playfer JR. Assessing caregiving distress: A conceptual analysis and a brief scale. British Journal of Clinical Psychology 2002, 41(4):387-403. 10.1348/014466502760387506, 12437793.
41. Elm JJ, Kamp C, Tilley BC, Guimaraes P, Fraser D, Deppen P, Brocht A, Weaver C, Bennett S, Investigators NN-P, et al. Self-reported adherence versus pill count in Parkinson's disease: the NET-PD experience. Movement Disorders 2007, 22(6):822-827. 10.1002/mds.21409, 17357141.
42. Peto V, Jenkinson C, Fitzpatrick R. PDQ-39: a review of the development, validation and application of a Parkinsopn's disease quality of life questionniare and its associated measures. Journal of Neurology 1998, 245(1):S10-S14. 10.1007/PL00007730, 9617716.
43. Peto V, Jenkinson C, Fitzpatrick R. Determining minimally important differences for the PDQ 39 Parkinson's disease questionnaire. Age and Ageing 2001, 30(4):299. 10.1093/ageing/30.4.299, 11509307.
44. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Movement Disorders 2008, 23(15):2129-2170. 10.1002/mds.22340, 19025984.
45. Chou KL, Amick MM, Brandt J, Camicioli R, Frei K, Gitelman D, Goldman J, Growdon J, Hurtig HI, Levin B, et al. A recommended scale for cognitive screening in clinical trials of Parkinson's disease. Movement Disorders 2010, 25(15):2501-2507. 10.1002/mds.23362, 2978783, 20878991.
46. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatrica Scandinavica 1983, 67(6):361-370. 10.1111/j.1600-0447.1983.tb09716.x, 6880820.
47. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale: An updated literature review. Journal of psychosomatic research 2002, 52(2):69-77. 10.1016/S0022-3999(01)00296-3, 11832252.
48. Gray R, Leese M, Bindman J, Becker T, Burti L, David A, Gournay K, Kikkert M, Koeter M, Puschner B, et al. Adherence Therapy for people with Schizophrenia. European multicentre randomised controlled trial. British Journal of Psychiatry 2006, 189:508-514. 10.1192/bjp.bp.105.019489, 17139034.
49. Gray R. Adherence Therapy: working together to improve health. A treatment manual for healthcare workers. University of East Anglia 2011, , http://eastanglia.academia.edu/RichardGray/Books/718181/Adherence_therapy_manual
50. Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Research in Psychology 2006, 3(2):77-101.
51. Alhalaiqa F, Deane KHO, Nawafleh AH, Clark A, Gray R. Adherence therapy for medication non-compliant patients with hypertension: a randomised controlled trial. J Hum Hypertens 2011,
52. Maneesakorn S, Robson D, Gournay K, Gray R. An RCT of adherence therapy for people with schizophrenia in Chiang Mai, Thailand. Journal of Clinical Nursing 2007, 16(0):1302-1312.
53. Staring ABP, Van der Gaag M, Koopmans GT, Selten JP, Van Beveren JM, Hengeveld MW, Loonen AJM, Mulder CL. Treatment adherence therapy in people with psychotic disorders: randomised controlled trial. The British Journal of Psychiatry 2010, 197(6):448-455. 10.1192/bjp.bp.110.077289, 21119150.
54. Grosset KA, Grosset DG. Effect of educational intervention on medication timing in Parkinson's disease: a randomized controlled trial. BMC Neurology 2007, 7(1):20. 10.1186/1471-2377-7-20, 1931606, 17634109.
55. A'Campo LEI, Wekking EM, Spliethoff-Kamminga NGA, Le Cessie S, Roos RAC. The benefits of a standardized patient education program for patients with Parkinson's disease and their caregivers. Parkinsonism & related disorders 2010, 16(2):89-95. 10.1016/j.parkreldis.2009.07.009, 22124833.
56. Coons S, Sheahan S, Martin S, Hendricks J, Robbins C, Johnson J. Predictors of medication noncompliance in a sample of older adults. Clinical Therapeutics 1994, 16(1):110.
57. MacLaughlin EJ, Raehl CL, Treadway AK, Sterling TL, Zoller DP, Bond CA. Assessing Medication Adherence in the Elderly: Which Tools to Use in Clinical Practice?. Drugs & Aging 2005, 22:231-255.
58. DiMatteo MR, Lepper HS, Croghan TW. Depression Is a Risk Factor for Noncompliance With Medical Treatment: Meta-analysis of the Effects of Anxiety and Depression on Patient Adherence. Arch Intern Med 2000, 160(14):2101-2107. 10.1001/archinte.160.14.2101, 10904452.
59. MacLaughlin EJ, Raehl CL, Treadway AK, Sterling TL, Zoller DP, Bond CA. Assessing Medication Adherence in the Elderly: Which tools to use in clinical practice?. Drugs Aging 2005, 22(3):231-255. 10.2165/00002512-200522030-00005, 15813656.